Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur.
Asian Pac J Allergy Immunol. 2014 Jun;32(2):145-52. doi: 10.12932/AP0359.32.2.2013.
To evaluate Malaysian patients' satisfaction levels and asthma control with Symbicort SMART® in the primary care setting.
This is a cross-sectional, multicentre study involving adult patients with persistent asthma who were prescribed only Symbicort SMART in the preceding one month prior to recruitment. Patients' satisfaction with Symbicort SMART and asthma control were evaluated using the self-administered Satisfaction with Asthma Treatment Questionnaire (SATQ) and the Asthma Control Test (ACT).
Asthma was controlled (ACT score >20) in 189 (83%) of 228 patients. The mean overall SATQ score for patients with controlled asthma was 5.65 indicating a high satisfaction level, which was positively correlated with high ACT scores. There were differences in asthma control based on ethnicity, number of unscheduled visits and treatment compliance.
Symbicort SMART resulted in a high satisfaction level and asthma control among Malaysian patients treated in the primary care setting and it is an effective and appealing treatment for asthmatic patients.
评估在初级保健环境中使用 Symbicort SMART®的马来西亚患者的满意度和哮喘控制水平。
这是一项横断面、多中心研究，纳入了在前一个月内仅被开具 Symbicort SMART 的成年持续性哮喘患者。使用自我管理的哮喘治疗满意度问卷 (SATQ) 和哮喘控制测试 (ACT) 评估患者对 Symbicort SMART 的满意度和哮喘控制情况。
228 例患者中有 189 例 (83%)哮喘得到控制 (ACT 评分>20)。控制组哮喘患者的平均总体 SATQ 评分为 5.65，表明满意度高，且与高 ACT 评分呈正相关。哮喘控制情况因种族、非计划性就诊次数和治疗依从性而异。
Symbicort SMART 在马来西亚初级保健环境中治疗的患者中实现了高满意度和哮喘控制，是一种对哮喘患者有效且有吸引力的治疗方法。
